Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ImmunoGen (IMGN) Q2 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates.

Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y

by Zacks Equity Research

Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.

AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised

by Zacks Equity Research

AbbVie (ABBV) matches second-quarter 2021 earnings estimates while beating the same for sales. Sales of new immunology drugs, Skyrizi and Rinvoq, reach $1 billion.

Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues

by Zacks Equity Research

Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.

TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up

by Zacks Equity Research

TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.

Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on any update related to guidance.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.

Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars

by Zacks Equity Research

Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.

Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.

AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS

by Zacks Equity Research

The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.

Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan

by Zacks Equity Research

Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.

Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

by Zacks Equity Research

The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.

Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.

Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study

by Zacks Equity Research

Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.

BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

by Zacks Equity Research

The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

Lilly's (LLY) Protomer Acquisition to Expand Diabetes Pipeline

by Zacks Equity Research

Lilly (LLY), which holds a 14% stake in private biotech company Protomer, acquires the remaining interest in it. The acquisition is set to expand Lilly's diabetes pipeline.

J&J (JNJ) Recalls Some Sunscreens Due to Benzene Presence

by Zacks Equity Research

J&J (JNJ) withdraws five aerosol sunscreen products from the market due to "low levels" of benzene found in some samples.

AstraZeneca (AZN) Gets Clearance in UK for Alexion Acquisition

by Zacks Equity Research

AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.

Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data

by Zacks Equity Research

Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.

Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

by Zacks Equity Research

Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.

AbbVie (ABBV) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study

by Zacks Equity Research

Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.

Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm

by Zacks Equity Research

The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.

WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara

by Zacks Equity Research

The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.

3 Reasons to Invest in Regeneron Pharmaceuticals (REGN) Now

by Zacks Equity Research

Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.